3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Tumor-Agnostic
1
Sarcoma
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
11
Fluorouracil
10
Oxaliplatin
8
Nivolumab
7
Leucovorin
6
Cisplatin
6
Capecitabine
6
Sorafenib
5
Ipilimumab
5
Cetuximab
5
Bevacizumab
5
Irinotecan
4
trifluridine tipiracil drug combination
3
trastuzumab deruxtecan
3
durvalumab
3
cabozantinib
3
Trastuzumab
3
Paclitaxel
3
zolbetuximab
2
trametinib
2
sodium thiosulfate
2
selpercatinib
2
relatlimab
2
lenvatinib
2
larotrectinib
2
encorafenib
2
dabrafenib
2
binimetinib
2
X-Rays
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
atezolizumab
×
Gastrointestinal
×
Clear all
NCT03434379
2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3
Completed
558 enrolled
48 charts
1 FDA